Healthpeak Properties, Inc. received 138,816,246 Janus Living Class A-1 shares and 75,917,780 Janus Living OP units through IPO formation transactions, providing 69.2% voting and economic rights as of September 30, 2026.
DOC · Healthpeak Properties, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Healthpeak raised 2026 adjusted FFO guidance for the third consecutive quarter, lifting the midpoint by two cents to a range of $1.76 to $1.78 per share, citing stronger portfolio leasing and operating performance.
Healthpeak reported third-quarter net income of $0.02 per share and FFO as Adjusted of $0.44 per share, increased full-year FFO as Adjusted guidance to $1.76 - $1.78, and reported Janus Living revenue of $268 million, up 78%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. Healthpeak raised FFO as Adjusted guidance, while Janus Living grew revenue and Adjusted EBITDAre, lab occupancy improved, and outpatient leasing remained strong. Investors still face lower diluted earnings guidance, negative Lab same-store performance and guidance, refinancing pressure, and an initial occupancy reset from the life science acquisitions.
- + Healthpeak raised its 2026 FFO as Adjusted guidance for the third consecutive quarter.
- + Janus Living delivered strong year-over-year revenue and Adjusted EBITDAre growth.
- + Lab occupancy and leasing momentum improved, with occupancy up 270 basis points since year-end 2025.
- + Outpatient Medical leasing remained strong, with year-to-date lease executions of 3.2 million square feet.
- + Healthpeak acquired or is under contract to acquire four life science buildings totaling approximately 510,000 square feet across three campuses for approximately $233 million.
- + Healthpeak had approximately $3.8 billion of liquidity as of October 30, 2026.
- − Healthpeak reduced its 2026 diluted earnings-per-share guidance by $0.10 at the midpoint.
- − Third-quarter diluted FFO as Adjusted per share was $0.44 versus $0.46 in the prior-year quarter.
- − Lab same-store adjusted NOI declined 0.7% year over year.
- − Healthpeak's full-year Lab same-store guidance remains negative at down 3% to down 6%.
- − Maturing debt carries an approximately 3% borrowing cost that is below current market rates.
- − The life science acquisitions will initially reduce reported occupancy because the acquired campuses are only 41% occupied.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjustments to NOI(1) non-GAAP | -62.69M | For the nine months ended September 30, 2026 | — |
| Annualized Adjusted EBITDAre(1) non-GAAP | 1.89B | Three Months EndedSeptember 30, 2026 | — |
| Current Quarter Total Property Count | 726 | As of September 30, 2026 | — |
| Diluted FFO as Adjusted per common share non-GAAP | $1.35 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Diluted Nareit FFO per common share non-GAAP | $1.31 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| EBITDAre | 432.37M | Three Months EndedSeptember 30, 2026 | — |
| Financial Leverage | 34.2% | September 30, 2026 | — |
| Fixed Charge Coverage Adjusted EBITDAre(2) non-GAAP | 462.77M | Three Months EndedSeptember 30, 2026 | — |
| Healthpeak's share of unconsolidated joint venture NOI | 34.94M | For the nine months ended September 30, 2026 | — |
|
|
|||
| Lab new and renewal lease executions | 480,000 | THIRD QUARTER 2026 | — |
| Lab total occupancy | 270 | since year-end 2025 | — |
| Nareit FFO applicable to common shares non-GAAP | 912.76M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Nine-Month SS Property Count | 593 | As of September 30, 2026 | — |
| NOI | 1.23B | For the nine months ended September 30, 2026 | — |
| Non-SS Adjusted NOI non-GAAP | -221.4M | For the nine months ended September 30, 2026 | — |
| Noncontrolling interests' share of consolidated joint venture NOI non-GAAP | 69.51M | nine months ended September 30, 2026 | — |
| Outpatient Medical lease executions | 3.2M | year-to-date | — |
| Outpatient Medical new and renewal lease executions | 846,000 | THIRD QUARTER 2026 | — |
| Portfolio Adjusted NOI non-GAAP | 1.17B | For the nine months ended September 30, 2026 | — |
| Same-store Adjusted NOI non-GAAP | 25.9% | third quarter | — |
| Secured Debt Ratio | 1.2% | September 30, 2026 | — |
| SS Adjusted NOI non-GAAP | 947.25M | For the nine months ended September 30, 2026 | — |
| Three-Month SS Property Count | 600 | As of September 30, 2026 | — |
| Total Adjusted Net Operating Income non-GAAP | $76M | third quarter | — |
| Adjusted NOI % change non-GAAP | 2.5% | Three Months Ended June 30, 2026 filing | — |
| Average annual base rent per occupied square foot | $67 | Three Months Ended June 30, 2026 filing | — |
| Average annual base rent per occupied square foot (Outpatient Medical Same-Store) | $29 | Three Months Ended June 30, 2026 filing | — |
| Average annual rent per occupied square foot | $92 | Three Months Ended June 30, 2026 filing | — |
| Average annual rent per occupied square foot (Outpatient Medical Same-Store) | $39 | Three Months Ended June 30, 2026 filing | — |
| Average occupancy | 90.5% | Three Months Ended June 30, 2026 filing | — |
| Average occupancy (Outpatient Medical Same-Store) | 91.9% | Three Months Ended June 30, 2026 filing | — |
| Average occupancy (Senior Housing Same-Store) | 88.6% | Three Months Ended June 30, 2026 filing | — |
| Average occupancy (Senior Housing Total Portfolio) | 85.5% | Three Months Ended June 30, 2026 filing | — |
| Average occupancy (Total Portfolio) | 87.7% | Three Months Ended June 30, 2026 filing | — |
| Average occupied square feet | 7.07M | Three Months Ended June 30, 2026 filing | — |
| Average occupied square feet (Outpatient Medical Same-Store) | 31.38M | Three Months Ended June 30, 2026 filing | — |
| Average occupied square feet (Total Portfolio) | 9.6M | Three Months Ended June 30, 2026 filing | — |
| Average occupied units (Senior Housing Same-Store) | 6,260 | Three Months Ended June 30, 2026 filing | — |
| Average occupied units (Senior Housing Total Portfolio) | 9,004 | Three Months Ended June 30, 2026 filing | — |
| End of period occupancy | 90.3% | Three Months Ended June 30, 2026 filing | — |
| End of period occupancy (Outpatient Medical Same-Store) | 91.9% | Three Months Ended June 30, 2026 filing | — |
| End of period occupancy (Outpatient Medical Total Portfolio) | 91.5% | Three Months Ended June 30, 2026 filing | — |
| End of period occupancy (Total Portfolio) | 87.5% | Three Months Ended June 30, 2026 filing | — |
| Property count | 101 | Three Months Ended June 30, 2026 filing | — |
| Property count (Outpatient Medical Same-Store) | 484 | Three Months Ended June 30, 2026 filing | — |
| Property count (Senior Housing Same-Store) | 15 | Three Months Ended June 30, 2026 filing | — |
| Property count (Senior Housing Total Portfolio) | 41 | Three Months Ended June 30, 2026 filing | — |
| Property count (Total Portfolio) | 141 | Three Months Ended June 30, 2026 filing | — |
| RevPOR per month (Senior Housing Same-Store) | $8,589 | Three Months Ended June 30, 2026 filing | — |
| RevPOR per month (Senior Housing Total Portfolio) | $7,484 | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDAre non-GAAP | $455.47M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationEBITDAre 440.68M (non-GAAP)
+9.17M Transaction, merger, and restructuring-related costs
-1.48M Other impairments (recoveries) and other losses (gains)
-5.51M Casualty-related charges (recoveries)
+12.87M Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization
+4.35M Stock-based compensation amortization expense
-4.61M Impact of transactions closed during the period
= Adjusted EBITDAre 455.47M
|
|||
| Adjusted EBITDAre (Janus Living) non-GAAP | $79M | the prior year quarter comparison, second quarter 2026 | — |
| Average occupied units/month | 8,672 | Six Months Ended June 30, 2026 | — |
| Diluted FFO as Adjusted applicable to common shares non-GAAP | 325.42M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationFFO as Adjusted applicable to common shares 321.03M (non-GAAP)
+4.38M Distributions on dilutive convertible units and other
= Diluted FFO as Adjusted applicable to common shares 325.42M
|
|||
| Diluted Nareit FFO applicable to common shares non-GAAP | $323.35M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationNareit FFO applicable to common shares 318.97M (non-GAAP)
+4.38M Distributions on dilutive convertible units and other
= Diluted Nareit FFO applicable to common shares 323.35M
|
|||
| Enterprise Debt | $10.24B | June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Consolidated Debt 10.03B
+212.25M Share of unconsolidated JV mortgage debt
= Enterprise Debt 10.24B
|
|||
| FFO as Adjusted applicable to common shares non-GAAP | 321.03M | three months ended June 30, 2026 | — |
| Healthpeak equity ownership of Janus Living | 73.6% | as of June 30, 2026 | — |
| Lab new lease executions | 222,000 | the second quarter | — |
| Lab renewal lease executions | 159,000 | the second quarter | — |
| Net Debt non-GAAP | 8.51B | June 30, 2026 | — |
GAAP → non-GAAP reconciliationEnterprise Debt 10.24B (the result of another reconciliation in this filing)
-1.63B Cash and cash equivalents
-9.29M Share of unconsolidated JV cash and cash equivalents
-91.86M Restricted cash
-1.65M Share of unconsolidated JV restricted cash
= Net Debt 8.51B
|
|||
| Outpatient Medical new lease executions | 327,000 | the second quarter | — |
| Outpatient Medical renewal lease executions | 916,000 | the second quarter | — |
| Portfolio Cash Real Estate Revenues non-GAAP | 689.86M | Three Months Ended June 30, 2026 | — |
| Same-store Adjusted NOI increase (Janus Living) non-GAAP | 19.2% | second quarter 2026 | — |
| Six-Month SS Property Count | 596 | Six Months Ended June 30, 2026 | — |
| SS Cash Real Estate Revenues non-GAAP | 564.28M | Three Months Ended June 30, 2026 | — |
| Total Adjusted Net Operating Income (Janus Living) non-GAAP | $58M | second quarter 2026 | — |
| Total occupancy (Lab) | 78.5% | the second quarter | — |
| Total occupancy (Outpatient Medical) | 90.7% | the second quarter | — |
| Year-Over-Year Same-Store Adjusted NOI Growth (Outpatient Medical) non-GAAP | 2.5% | Three Month | — |
| Year-Over-Year Same-Store Adjusted NOI Growth (Senior Housing) non-GAAP | 19.2% | Three Month | — |
| Year-Over-Year Same-Store Adjusted NOI Growth (Total) non-GAAP | 1.8% | Three Month | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOC
this stock
Healthpeak Properties, Inc.
|
$13.78B | +24.3% | +4.5% | 37.0 | 3.3% |
|
WELL
Welltower Inc.
|
$179.34B | +31.7% | +35.6% | 106.3 | 2.4% |
|
VTR
Ventas, Inc.
|
$47.02B | +14.9% | +18.5% | 167.8 | 2.8% |
|
OHI
Omega Healthcare Investors Inc
|
$14.32B | +6.1% | +13.2% | 18.9 | 4.8% |
|
AHR
American Healthcare REIT, Inc.
|
$13.41B | +22.8% | +9.1% | 115.6 | 14.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 15
Healthpeak Properties, Inc. received 138,816,246 Janus Living Class A-1 shares and 75,917,780 Janus Living OP units through IPO formation transactions, providing 69.2% voting and economic rights as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOC | -1.4% | +5.3% | -0.3% | +5.0% | +24.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.0% | +6.4% | -0.8% | +5.2% | +13.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.